Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female volunteers aged 18-45 years.~* Able and willing (in the investigator's opinion) to comply with all trial requirements.~* General good health based on history and clinical examination~* Written informed consent~* Women only: Must agree to practice continuous effective contraception for the duration of the trial (a method which results in a low failure rate; i.e. less than 1% per year). Women will be counseled about effective contraception methods and, if required, can be provided with adequate contraceptives by the investigator team.~* Available to participate in follow up for the duration of trial (36 weeks following first injection)~* Reachable by phone during the whole trial period~Exclusion Criteria:~* Pregnancy, lactation or intention to become pregnant during the trial~* Previous participation in a malaria vaccine trial~* HIV infection~* Any confirmed or suspected immunosuppressive or immunodeficient state, asplenia, recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)~* Presence of autoimmune diseases requiring systemic treatment (e.g. rheumatic diseases)~* Use of immunoglobulins or blood products within 3 months prior to enrolment~* Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the trial period~* History of malaria or travel in malaria-endemic areas within the past 6 months~* Intention to travel to malaria endemic countries during the trial period~* History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)~* History of serious psychiatric condition that may affect participation in the trial~* Any other serious chronic illness requiring hospital specialist supervision~* Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 60 g (men) or 40 g (women) per day or a carbohydrate deficient transferrin (CDT) level ≥2.5%~* Suspected or known injecting drug abuse in the 5 years preceding enrolment~* Positive for hepatitis B surface antigen (HBs-antigen)~* Seropositive for hepatitis C virus (antibodies to HCV)~* Volunteers unable to be closely followed for social, geographic or psychological reasons~* Known hypersensitivity to any of the vaccine components (adjuvant or peptide)~* Any clinically significant abnormal finding on biochemistry or hematology blood tests, urine analysis or clinical examination~* History of seizure, except for sporadic febrile convulsions in childhood~* Any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the trial; affect the ability of the volunteer to participate in the trial or impair interpretation of the trial data.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1A - 20 µg PAMVAC + Alhydrogel (Type: EXPERIMENTAL): The study participant will get 20 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
- 2A - 20 µg PAMVAC + GLA-SE (Type: EXPERIMENTAL): The study participant will get 20 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
- 3A - 20 µg PAMVAC + GLA-LSQ (Type: EXPERIMENTAL): The study participant will get 20 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)
- 4A - 50 µg PAMVAC + Alhydrogel (Type: EXPERIMENTAL): The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
- 5A - 50 µg PAMVAC + GLA-SE (Type: EXPERIMENTAL): The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
- 6A - 50 µg PAMVAC + GLA-LSQ (Type: EXPERIMENTAL): The study participant will get 50 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)
- 1B - 50 µg PAMVAC + Alhydrogel (Type: EXPERIMENTAL): The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
- 2B - 50 µg PAMVAC + GLA-SE (Type: EXPERIMENTAL): The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
- 3B - 100 µg PAMVAC + Alhydrogel (Type: EXPERIMENTAL): The study participant will get 100 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
- 4B - 100 µg PAMVAC + GLA-SE (Type: EXPERIMENTAL): The study participant will get 100 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
- 5B - Placebo (Type: PLACEBO_COMPARATOR): The study participant will get Placebo (physiological saline solution) administrated three times with each time 28 days interval (day 0-28-56)

Based on this trial design, predict the completion outcome and termination type (if applicable).